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Background. Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess 
formation and embolic events, there is limited evidence to support this assumption.
Methods. We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG 
endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci 
(VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis.
Results. Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/
SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When com-
paring SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, P = .116); valve dis-
order, including perforation (22.2% vs 18.1%, P = .584), pseudoaneurysm (16.7% vs 8.3%, P = .108), or prosthesis dehiscence (1.4% 
vs 6.3%, P = .170); paravalvular complications, including abscess (25% vs 18.8%, P = .264) and intracardiac fistula (5.6% vs 3.5%, 
P = .485); heart failure (34.7% vs 38.9%, P = .655); or embolic events (41.7% vs 32.6%, P = .248). Indications for surgery (70.8% vs 
70.8%; P = 1) and mortality (13.9% vs 16.7%; P = .741) were similar between groups.
Conclusions. SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG.
Keywords.  infective endocarditis; Streptococcus anginosus; viridans group streptococci; Streptococcus gallolyticus.
Infective endocarditis is one of the most life-threatening infec-
tions encountered in clinical practice and still represents a sig-
nificant diagnostic and therapeutic challenge. About 40%–50% 
of patients with endocarditis require valve surgery at some 
point during the clinical course and mortality remains around 
20%–25% in the first year after diagnosis [1].
In recent years, epidemiological changes in endocarditis have 
been documented in high-income countries, with an increasing 
rate of episodes caused by staphylococci and enterococci [2, 
3]. Nevertheless, streptococci are still a major cause of endo-
carditis, mostly in developing countries [4]. Concerning strep-
tococcal endocarditis, there is a clear predominance of cases 
due to viridans group streptococci (VGS), whereas β-hemolytic 
streptococci [5] and Streptococcus anginosus group (SAG) 
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[1] are identified less often as causative agents. The species 
encompassing SAG (Streptococcus anginosus, Streptococcus 
intermedius, and Streptococcus constellatus) are known for their 
propensity to cause pyogenic infection and abscess formation 
in the head, neck, or abdomen. SAG can also cause bacteremia 
and, more rarely, endocarditis [6, 7].
Although endocarditis caused by SAG is thought to be asso-
ciated with valve destruction, abscess formation, and embolic 
events [8], little information is available to support the assump-
tion that it is more severe than other causes. We therefore aimed 
to characterize the main clinical features and outcomes of en-
docarditis caused by SAG and compared this with endocarditis 
and cases due to VGS or Streptococcus gallolyticus group (SGG) 
in a large cohort of patients with infective endocarditis.
METHODS
Patient Population and Data Collection
This was a large multicenter cohort study of consecutive adult 
patients with a definite diagnosis of endocarditis at 27 dif-
ferent Spanish hospitals (24 of them included within the Grupo 
de Apoyo al Manejo de la Endocarditis Infecciosa en España 
[GAMES] prospective cohort) and 1 Italian hospital. GAMES is 
a prospective registry into which multidisciplinary teams pro-
spectively record all consecutive episodes of endocarditis since 
2008 [9]. We therefore performed a retrospective analysis of 
prospectively collected data for the period 2008–2017, using a 
standardized case report form. Data included demographic and 
clinical variables, echocardiography findings, treatment, and 
outcomes, namely septic shock, valvular and paravalvular com-
plications, heart failure, embolic events, indication for surgery, 
and mortality.
We analyzed all cases of definite endocarditis due to SAG 
and compared these with cases due to VGS or SGG using a 1:2 
matched analysis. Matching was performed according to the 
type of valve (native or prosthetic), patient’s sex, age (±5 years), 
year of diagnosis, and when feasible, hospital. Episodes of 
device-related infection (pacemaker and implantable defibril-
lators) and isolated right-side valve endocarditis were excluded.
Definitions
Definite infective endocarditis was defined according to the 
modified Duke criteria [10, 11]. Acquisition was categorized 
as community-acquired or non-community-acquired, with the 
latter including nosocomial-acquired and health care–asso-
ciated infections [12]. All patients were followed up for up to 
1 year and were considered cured in the absence of relapse or 
death. Relapse during follow-up was defined as positive blood 
cultures with the same microorganism. A new episode of endo-
carditis caused by a different microorganism was classified as a 
reinfection. Embolic events were defined as radiological findings 
consistent with ischemia of a major organ, either symptomatic 
or asymptomatic. Request for imaging tests was made at the dis-
cretion of the treating physicians. Acute kidney injury was de-
fined as an abrupt decrease in kidney function with an increase 
of at least 1.5-fold in serum creatinine levels. Heart conduction 
disorders were defined as newly identified auriculoventricular 
blockage or heart bundle blockage. Septic shock was defined as 
hypotension persisting despite adequate fluid resuscitation [13, 
14]. Indication for surgery was considered for heart failure due 
to valve regurgitation, intracardiac complications, or signs of 
uncontrolled infection, as listed in both the European and US 
guidelines [11, 15]. Overall mortality was defined as all-cause 
death during follow-up. Endocarditis-related mortality was de-
fined as death during active antibiotic treatment at initial hospi-
talization or when occurring as a complication of valve surgery.
Microbiological Identification
Identification of microorganisms to the species level was per-
formed according to standard methods in each participating 
center [16]. Before 2011, bacteria isolated from blood culture 
isolates were identified using conventional biochemical tests or 
by 16S polymerase chain reaction and sequencing in cases of in-
conclusive results. Since 2011, isolates have been identified using 
matrix-assisted laser desorption/ionization–time of flight in the 
majority of the participant hospitals. Viridans group streptococci 
included Streptococcus mitis group (S mitis, S oralis, S sanguinis, 
S parasanguinis, S gordonii), Streptococcus mutans group (S 
mutans), and Streptococcus salivarius group (S salivarius). 
Streptococcus gallolyticus group included 4 subspecies: gallolyticus, 
pasteurianus, infantarius, and lutetiensis. Streptococcus anginosus 
group included S anginosus, S constellatus, and S intermedius. 
Antibiotic susceptibility was evaluated according to the Clinical 
and Laboratory Standards Institute recommendations.
Statistical Analysis
Categorical variables are expressed as frequencies and percent-
ages. Continuous variables are expressed as mean and standard 
deviation (SD). Qualitative variables were compared using χ 2 
or Fisher exact tests, and quantitative variables were compared 
using the Student t test or Mann-Whitney U test, as appropriate. 
Statistical significance was set at P < .05, and all P values were 
2-sided. Analyses were performed using IBM SPSS version 20 
(IBM Corporation, Armonk, New York).
Ethical Considerations
This observational study was conducted in accordance with 
the Declaration of Helsinki and was approved by the regional 
ethics committee (Comité Ético de Investigación Clínica 
Regional de la Comunidad de Madrid, approval code 07/18). 
To protect personal privacy, identifying information in the 
electronic database was encrypted for each patient. Written 
informed consent was obtained from all patients reviewed 
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ethics committee in each of the Barcelona Endocarditis Study 
Team (BEST) participating hospitals because no intervention 
was involved and no patient-identifying information was 
included.
RESULTS
Clinical Characteristics and Outcomes of SAG Endocarditis
During the study period, 5336 episodes of definite endocar-
ditis were recorded in the participating hospitals. Of these, 72 
cases (1.4%) were due to SAG, and these cases were matched 
with 144 controls of patients with VGS or SGG endocarditis. 
Characteristics by infective agent are detailed in Tables 1 and 
2. Most cases of SAG (76%) occurred in men, and the mean 
age was 67 years (SD, 16 years). Most cases were community-
acquired (90%) and affected native valves (80.6%). The aortic 
valve was involved most often (40.3%), followed by the mi-
tral valve (38.9%) and the aortic and mitral valves combined 
(19.4%).
New valve regurgitation developed in 20 (27.8%) patients, 
with severe mitral regurgitation being the most frequent. 
Notably, 15 patients (20.9%) suffered some form of intracra-
nial hemorrhage and 14 (19.4%) suffered splenic emboli. Acute 
heart failure occurred in 34.7%, with 26.4% of cases having a 
New York Heart Classification III or IV. Acute kidney injury 
occurred in 20.8%, heart conduction disorders in 15.3%, and 
septic shock in 8.3%, but there were no cases of symptomatic 
osteoarticular involvement.
All patients received β-lactams as backbone antibiotic 
therapy, in 37 cases (51%) in synergic combination with genta-
micin. The mean antibiotic treatment length was 34.5 days (SD, 
12.6 days). Although more than two-thirds of cases had an in-
dication for surgery, it was eventually not performed in 14% due 
to a poor prognosis and/or lack of patient consent. There was an 
elective indication in 33% of surgeries. Ultimately, 83% of cases 
were deemed to have been cured. Overall mortality occurred 
in 10 patients (14%), all cases considered endocarditis-related 
mortality due to peri- or postoperative complications, severe 
bleeding, multiorgan failure, and septic or cardiogenic shock.
Microbiology
The most frequently isolated microorganism in SAG endocar-
ditis was S anginosus (n = 40 [55%]), followed by S constellatus 
(n = 15 [20%]) and S intermedius (n = 7 [10%]). In 10 (14%) 
cases, a SAG microorganism was isolated but not identified to 
the species level. Among the cases of VGS/SGG endocarditis, S 
mitis was the most commonly isolated microorganism (n = 40 
[28%]), followed by S oralis (n = 22 [15%]), S sanguinis (n = 20 
[14%]), and other species (Table 3). In 29 (20%) cases of VGS/
Table 1. Comparative Analysis of General Characteristics and Clinical Manifestations of Infective Endocarditis Caused by Streptococcus anginosus 
Group and Viridans Group Streptococci/Streptococcus gallolyticus Group
Characteristic SAG Endocarditis (n = 72) VGS or SGG Endocarditis (n = 144) P Value
Male sex 55 (76.4) 106 (73.6) .846
Mean age, y (SD) 67 (16) 68 (15) .845
Chronic lung disease 12 (16.7) 23 (16) 1.000
Diabetes mellitus 16 (22.2) 22 (15.3) .283
Chronic kidney disease 6 (8.3) 18 (12.5) .491
Age-adjusted Charlson index, y, mean (SD) 3.8 (2.6) 3.7 (2.5) .960
Acquisition   .834
 Community-acquired 64 (88.9) 133 (92.4) .552
 Non-community-acquired 6 (8.4) 9 (6.3) .776
Type of endocarditis   .951
 Native 58 (80.6) 118 (81.9) .951
 Prosthetic 14 (19.4) 26 (18.1) .951
Affected valve   .876
 Aortic 29 (40.3) 60 (41.7) .961
 Mitral 28 (38.9) 52 (36.1) .803
 Mitral and aortic 14 (19.4) 26 (18.1) .950
Embolic phenomena 30 (41.7) 47 (32.6) .248
 Central nervous system emboli 18 (25) 22 (15.3) .122
Echocardiographic findings    
 Perforation or valve rupture 16 (22.2) 26 (18.1) .584
 Pseudoaneurysm 12 (16.7) 12 (8.3) .108
 Abscess 18 (25) 27 (18.8) .264
 Intracardiac fistula 4 (5.6) 5 (3.5) .485
 Prosthesis dehiscence 1 (1.4) 9 (6.3) .170
Data are presented as No. (%) unless otherwise indicated.
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SGG endocarditis, identification was not performed to the 
species level.
Comparative Analysis of SAG and VGS/SGG Endocarditis
Tables 1 and 2 show the comparison between SAG and VGS/
SGG endocarditis. There were no statistically significant differ-
ences in either valve involvement (perforation: 22.2% vs 18.1%, 
P = .584; pseudoaneurysm: 16.7% vs 8.3%, P = .108; prosthesis 
dehiscence: 1.4% vs 6.3%, P = .170) or paravalvular complica-
tions (abscess: 25% vs 18.8%, P = .264; intracardiac fistula: 5.6% 
vs 3.5%, P = .485). Equally, no significant differences were de-
tected between SAG and VGS/SGG endocarditis when com-
paring the rate of acute heart failure (34.7% vs 38.9%, P = .655), 
heart conduction disorders (15.3% vs 12.5%, P = .739), septic 
shock (8.3% vs 3.5%, P = .116), indication for surgery (70.8% vs 
70.8%, P = 1), or overall mortality (13.9% vs 16.7%, P = .741). 
There was 1 case of relapse due to S oralis. No molecular typing 
was performed.
DISCUSSION
In this largest study of SAG endocarditis to date, we found 
that SAG accounted for 1.4% of all definite cases of endocar-
ditis in our cohort. This figure concurs with that reported in 
a previous study of 18 patients [17]. Also in accordance with 
previous observations, we found that S.  anginosus was the 
most commonly identified causative species in SAG endo-
carditis [8, 18].
Controversy remains about the true virulence of SAG in in-
fective endocarditis. Some sporadic case reports depict SAG en-
docarditis as an aggressive infection with frequent intracardiac 
complications, embolic events, and abscess formation [19–21]. 
In a retrospective study of 56 cases of endocarditis caused by 
β-hemolytic streptococci, 29 cases of SAG endocarditis had a 
less aggressive presentation and fewer extracardiac complica-
tions [1]. However, the conclusions in previous studies are lim-
ited by the limited by the small number of cases of endocarditis 
caused by SAG.
We observed no statistically significant differences when com-
paring SAG with VGS/SGG endocarditis regarding either local 
complications (valve perforation or abscess, pseudoaneurysm, 
prosthesis dehiscence, or intracardiac fistula) or systemic 
Table 3. Distribution of Viridans Group Streptococci or Streptococcus 
gallolyticus Group Isolates Causing Endocarditis, by Species
Species of Microorganism Frequency (%)
Streptococcus mitis 40 (27.8)
Nonidentified Streptococcus viridans group 29 (20.1)
Streptococcus oralis 22 (15.3)
Streptococcus sanguinis 20 (13.9)
Streptococcus salivarius 12 (8.3)
Streptococcus mutans 9 (6.3)
Streptococcus gordonii 8 (5.6)
Streptococcus gallolyticus group 3 (2.1)
Streptococcus parasanguinis 1 (0.7)
Table 2. Comparative Analysis of Treatment and Outcomes of Infective Endocarditis Caused by Streptococcus anginosus Group and Viridans Group 
Streptococci/Streptococcus gallolyticus Group
Characteristic SAG Endocarditis (n = 72) VGS or SGG Endocarditis (n = 144) P Value
Treatment duration, d, mean (SD) 34.5 (12.6) 33.8 (10.8) .854
Combination treatment with gentamicin 37 (51) 82 (56.9) .494
Complications
 Acute heart failure 25 (34.7) 56 (38.9) .655
 Persistent bacteremia 4 (5.6) 8 (5.6) .602
 Heart conduction disorder 11 (15.3) 18 (12.5) .739
 Acute kidney injury 15 (20.8) 44 (30.6) .177
 Septic shock 6 (8.3) 5 (3.5) .116
Surgery
 Surgery indicated 51 (70.8) 102 (70.8) 1
 Elective 24 (33.3) 47 (32.6) 1
 Urgent 12 (16.7) 19 (13.2) .618
 Emergent 5 (6.9) 7 (4.9) .749
Surgery indicated but not performed 10 (13.9) 29 (20.1) .348
Prognosisa
 Definitely cured 60 (83.3) 114 (79.2) .584
 Overall mortality 10 (13.9) 24 (16.7) .741
  Endocarditis-related mortality 10 (13.9) 16 (11.1) .711
 Relapse 0 1 (0.7)  
 Reinfection 0 2 (1.4)  
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: SAG, Streptococcus anginosus group; SD, standard deviation; SGG, Streptococcus gallolyticus group; VGS, viridans group streptococci.
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complications (heart failure and septic shock). Similarly, we 
found no differences in the proportion of patients with sur-
gical indications nor in mortality. These results are consistent 
with those of a previous study in which SAG endocarditis had a 
comparable prognosis to VGS/SGG endocarditis [17]. It could 
be hypothesized that prior observations reporting a higher 
virulence of SAG endocarditis may have been biased toward 
describing the most severe cases. It should be noted, however, 
that higher rates of pseudoaneurysms, intracardiac abscess, 
and central nervous system emboli were actually identified, 
although without achieving statistical significance. Anatomic 
damage and prognostic differences may ultimately be subtle 
and difficult to detect; thus, the non–statistically significant dif-
ferences observed could reflect a type II statistical error due to 
the limited number of SAG endocarditis cases in our cohort.
Our study has some limitations that should be acknowl-
edged. Due to its retrospective design, some information such 
as the formation of extracardiac abscesses was not available for 
comparison between groups. Moreover, the small number of 
cases with certain complications, such as prosthesis dehiscence 
or intracardiac fistula, diminishes the power of these analyses. 
On the other hand, the well-known difficulties for the accurate 
identification of streptococcal species and some changes in the 
microbiological tools used for this task throughout the study 
period should be recognized as another potential limitation. 
We believe, however, that the multicenter nature of this study 
and the contemporary period of data collection strengthen our 
results.
In conclusion, SAG endocarditis is an infrequent but serious 
condition that follows a similar clinical course to VGS/SGG 
endocarditis, regarding valvular complications and prognostic 
variables such as indication for surgery or endocarditis-related 
mortality.
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